- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Severe skin toxicity due to weekly paclitaxel administration ; volume:36 ; number:01 ; year:2015 ; pages:62-62
Indian journal of medical & paediatric oncology ; 36, Heft 01 (2015), 62-62
- Beteiligte Personen und Organisationen
-
Kate, Shruti
Gulia, Seema
Gupta, Sudeep
- DOI
-
10.4103/0971-5851.151795
- URN
-
urn:nbn:de:101:1-2021083009564231047594
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kate, Shruti
- Gulia, Seema
- Gupta, Sudeep
Ähnliche Objekte (12)
Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
Weekly paclitaxel in escalating doses in a patient with anthracycline-resistant, triple-negative, metastatic breast cancer with severe liver dysfunction
Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John’s wort skin oil
Severe Photo Toxicity Recalled by Docetaxel
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival
A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer
Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients
Incidence of Neuropathy with Weekly Paclitaxel and Role of Oral Glutamine Supplementation for Prevention of Paclitaxel Induced Peripheral Neuropathy Randomized Controlled Trial
Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
Weekly paclitaxel in escalating doses in a patient with anthracycline-resistant, triple-negative, metastatic breast cancer with severe liver dysfunction
Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John’s wort skin oil
Severe Photo Toxicity Recalled by Docetaxel
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival
A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer
Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients
Incidence of Neuropathy with Weekly Paclitaxel and Role of Oral Glutamine Supplementation for Prevention of Paclitaxel Induced Peripheral Neuropathy Randomized Controlled Trial
Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
Weekly paclitaxel in escalating doses in a patient with anthracycline-resistant, triple-negative, metastatic breast cancer with severe liver dysfunction
Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John’s wort skin oil
Severe Photo Toxicity Recalled by Docetaxel
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival
A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer
Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients